Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Austin N Kirschner

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Journal of Virology|June 22, 2007
Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusionAustin N Kirschner, Amanda S Lowrey, Richard Longnecker, et al.
Virus Genes|February 18, 2010
Characteristics of Epstein-Barr virus envelope protein gp42Pamela L Shaw, Austin N Kirschner, Theodore S Jardetzky, et al.
Plos One|April 2, 2019
Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathwayKonjeti R Sekhar, Jian Wang, Michael L Freeman, et al.
Journal of Virology|July 30, 2010
Mapping the N-terminal residues of Epstein-Barr virus gp42 that bind gH/gL by using fluorescence polarization and cell-based fusion assaysFengling Liu, Gaby Marquardt, Austin N Kirschner, et al.
Journal of Virology|September 16, 2006
Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusionAustin N Kirschner, Jasmina Omerovic, Boris Popov, et al.
World Journal of Clinical Oncology|January 10, 2019
Radiation-associated epithelial-myoepithelial carcinoma among five secondary malignancies: A case report and review of literatureMohamed H Khattab, Alexander D Sherry, Carolyn G Ahlers, et al.
Journal of Contemporary Brachytherapy|May 3, 2014
Multisector dosimetry in the immediate post-implant period: significant under dosage of the prostate baseAustin N Kirschner, Vythialingam Sathiaseelan, Yunkai Zhang, et al.
American Journal of Clinical Oncology|November 22, 2022
Evaluation of 5 Fraction Stereotactic Body Radiation Therapy (SBRT) for Osseous Renal Cell Carcinoma MetastasesAustin P H Dove, Alex Wells, Wu Gong, et al.
American Journal of Clinical Oncology|September 20, 2011
Trends in the use of postoperative radiation therapy in patients with localized resectable pancreatic cancerEric T Shinohara, Nandita Mitra, Wan Fei, et al.
BJU International|March 24, 2023
Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse modelWoodson W Smelser, Jian Wang, Kristen M Ogden, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Journal of Virology|June 22, 2007
Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusionAustin N Kirschner, Amanda S Lowrey, Richard Longnecker, et al.
Virus Genes|February 18, 2010
Characteristics of Epstein-Barr virus envelope protein gp42Pamela L Shaw, Austin N Kirschner, Theodore S Jardetzky, et al.
Plos One|April 2, 2019
Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathwayKonjeti R Sekhar, Jian Wang, Michael L Freeman, et al.
Journal of Virology|July 30, 2010
Mapping the N-terminal residues of Epstein-Barr virus gp42 that bind gH/gL by using fluorescence polarization and cell-based fusion assaysFengling Liu, Gaby Marquardt, Austin N Kirschner, et al.
Journal of Virology|September 16, 2006
Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusionAustin N Kirschner, Jasmina Omerovic, Boris Popov, et al.
World Journal of Clinical Oncology|January 10, 2019
Radiation-associated epithelial-myoepithelial carcinoma among five secondary malignancies: A case report and review of literatureMohamed H Khattab, Alexander D Sherry, Carolyn G Ahlers, et al.
Journal of Contemporary Brachytherapy|May 3, 2014
Multisector dosimetry in the immediate post-implant period: significant under dosage of the prostate baseAustin N Kirschner, Vythialingam Sathiaseelan, Yunkai Zhang, et al.
American Journal of Clinical Oncology|November 22, 2022
Evaluation of 5 Fraction Stereotactic Body Radiation Therapy (SBRT) for Osseous Renal Cell Carcinoma MetastasesAustin P H Dove, Alex Wells, Wu Gong, et al.
American Journal of Clinical Oncology|September 20, 2011
Trends in the use of postoperative radiation therapy in patients with localized resectable pancreatic cancerEric T Shinohara, Nandita Mitra, Wan Fei, et al.
BJU International|March 24, 2023
Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse modelWoodson W Smelser, Jian Wang, Kristen M Ogden, et al.
Pageof 5